No study has reported the relationship between secondhand smoke (SHS) exposure and hypertension in self-reported never-smokers verified by nicotine metabolite. The aim of this study is to determine the relationship between SHS exposure and hypertension in self-reported and cotinine-verified never-smokers. A total of 106,268 self-reported never-smokers, verified as nonsmokers by urinary cotinine, who participated in Kangbuk Samsung Cohort study (KSCS) between 2012 and 2016 were included. Cotinine-verified nonsmokers were defined as individuals having urinary cotinine <50 ng/mL. SHS exposure was defined as current exposure to passive smoke indoors at home or the workplace. The multivariate regression model revealed that SHS exposure was associated with hypertension (odds ratio (OR) (95% confidence interval (CI)), 1.16 (1.08, 1.24)). Current SHS exposure that has been exposed to home SHS (1.22 (1.11, 1.33)) as well as current SHS exposure only at the workplace (1.15 (1.02, 1.29)) significantly increased the ORs for hypertension compared to no SHS exposure. There was no significant gender interaction for the relationships between SHS exposure and hypertension. This study showed that SHS exposure was significantly associated with hypertension in self-reported never-smokers verified as nonsmokers by urinary cotinine, suggesting necessity of health program and stricter smoking regulation to reduce the risk of hypertension.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723357 | PMC |
http://dx.doi.org/10.3390/jcm8081238 | DOI Listing |
JAMA Pediatr
January 2025
Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Importance: Data regarding the long-term impact of treating childhood obesity on the risk of obesity-related events, including premature mortality, are limited.
Objective: To evaluate the long-term effect of different responses to pediatric obesity treatment on critical health outcomes in young adulthood.
Design, Setting, And Participants: The study included a dynamic prospective cohort of children and adolescents with obesity within The Swedish Childhood Obesity Treatment Register (BORIS) and general population comparators, linked with national registers.
J Hypertens
December 2024
Service de pharmacologie médicale et clinique, faculté de médecine, Centre Hospitalier Universitaire.
Objective: Ibrutinib has been the first Bruton tyrosine kinase inhibitor (BTKi) authorized for the treatment of B-cell lymphoproliferative disorders (B-LPDs). Numerous publications have confirmed the efficacy of this orally administrated drug in chemo-free regimens for B-LPDs. They also reported several adverse events (AE) associated with ibrutinib treatment.
View Article and Find Full Text PDFFront Nutr
January 2025
Department of Nephrology, Dongfang Hospital of Beijing University of Chinese Medicine, Beijing, China.
Background: The oxidative balance score (OBS) is a comprehensive concept that includes 16 dietary components and four lifestyle factors to assess an individual's exposure to pro-oxidants and antioxidants. This study aims to explore the relationship between OBS and the risk of chronic kidney disease (CKD).
Methods: This cross-sectional study included nationally representative National Health and Nutrition Examination Survey (NHANES) participants aged 18 and above from 2005 to 2018.
Mindfulness (N Y)
May 2024
Department of Pediatrics, UCI School of Medicine, University of California Irvine, 3800 W. Chapman Ave, Suite 2200, Orange, CA 92868, USA.
Objectives: Cardiometabolic health during pregnancy has potential to influence long-term chronic disease risk for both mother and offspring. Mindfulness practices have been associated with improved cardiometabolic health in non-pregnant populations. The objective was to evaluate diverse studies that explored relationships between prenatal mindfulness and maternal cardiometabolic health.
View Article and Find Full Text PDFClin Pharmacol Drug Dev
January 2025
Department of Pathology, Xianning Central Hospital, The First Affiliated Hosptial of Hubei University of Science and Technology, Xianning, Hubei, P.R. China.
Bosentan is a dual endothelin receptor antagonist widely used in the treatment of pulmonary artery hypertension. However, there are few reports on the pharmacokinetics (PK) and bioequivalence of bosentan dispersible tablets (32 mg) in the Chinese population. This study aimed to evaluate the PK characteristics and bioequivalence of the test and reference formulations of bosentan dispersible tablets in healthy Chinese volunteers under fasting and fed conditions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!